EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Cancer (EXERT-C)
EXERT-C: Prospective Study of an EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Samantha Campbell
- Phone Number: (412) 330-6151
- Email: samantha.campbell@ahn.org
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15202
- Recruiting
- AHN CI Exercise Oncology and Resiliency Center
-
Contact:
- Colin E Champ, MD, CSCS
- Phone Number: 412-734-7605
- Email: colin.champ@ahn.org
-
Sub-Investigator:
- Chris Peluso, BS
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 20-89 years
- Women of child-bearing potential must verbally confirm lack of pregnancy prior to enrollment. They should also consent to use adequate contraception during the course of the study.
- Participants must be determined capable of engaging in resistance training by exercise personnel and/or study PI
- Participants must complete an assessment by EOC staff and be determined safe to engage in the workout regimen by the study exercise personnel.
- Individuals not deemed safe to participate in the standard EOC exercise program will be referred to physical therapy or elsewhere
Exclusion Criteria:
1. Severe arthritic, joint, cardiovascular, or musculoskeletal condition that would interfere with exercise program
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
General cancer patients
All patients undergoing treatment for cancer on an exercise regimen
|
All individuals will be engaging in resistance training during and/or after their cancer treatment
|
|
Head and neck cancer patients
All patients undergoing treatment for head and neck cancer on an exercise regime
|
All individuals will be engaging in resistance training during and/or after their cancer treatment
|
|
Colorectal cancer patients
All patients undergoing treatment for colorectal cancer on an exercise regime
|
All individuals will be engaging in resistance training during and/or after their cancer treatment
|
|
Pancreatic cancer patients
All patients undergoing treatment for pancreatic cancer on an exercise regime
|
All individuals will be engaging in resistance training during and/or after their cancer treatment
|
|
Metastatic breast cancer patients
All patients undergoing treatment for metastatic breast cancer on an exercise regime
|
All individuals will be engaging in resistance training during and/or after their cancer treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determine changes in fat mass in pounds from before to after the nutrition and exercise regimen via bioimpedance analysis
Time Frame: 3 months
|
Measurement on bioimpedance analysis machine (Inbody 970)
|
3 months
|
|
Determine changes in fat mass in pounds from before to after the nutrition and exercise regimen via ultrasound
Time Frame: 3 months
|
Measurement via ultrasound and calculation with Jackson-Pollack calculations
|
3 months
|
|
Determine changes in muscle mass in pounds from before to after the nutrition and exercise regimen
Time Frame: 3 months
|
Measurement on bioimpedance analysis machine (Inbody 970)
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determine changes in EQ-5D responses 1-5 and overall score from before to after the nutrition and exercise regimen
Time Frame: 3 months
|
EQ-5D asks 5 questions rates from 1-5 and an overall rating of health
|
3 months
|
|
Determine changes in strength via load measured in pounds from before to after the nutrition and exercise regimen
Time Frame: 3 months
|
Load is calculated by multiplying sets by repetitions by weight lifted for a specific exercise
|
3 months
|
|
Determine changes in Y-balance score for each leg
Time Frame: 3 months
|
Y-balance score adds up the distance each leg can move in the front and side directions, divided by the length of the hip.
This correlates inversely with fall risk.
|
3 months
|
|
Determine changes in overall score of functional movement screen (FMS) from before to after the nutrition and exercise regimen
Time Frame: 3 months
|
Determine changes in overall score of functional movement screen (FMS) from before to after the nutrition and exercise regimen
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2023-021-SG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.